{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059109","form_type":"8-K","ticker":null,"cik":"0001657312","company_name":"Verona Pharma plc","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.459670+00:00","generated_at":"2026-06-02T06:12:36.434580+00:00","sec_items":["1.01","1.02","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Verona Pharma secures up to $650M strategic financing from Oaktree and OMERS for ensifentrine launch","bullets":["Debt facility of $400M in five tranches; $55M drawn at close, $70M upon FDA approval, $175M on sales milestones, $100M discretionary.","Revenue interest agreement (RIPSA) up to $250M; $100M upon FDA approval, $150M on sales milestones; capped at 1.75x funded amount.","Debt interest 11% p.a., interest-only quarterly, maturity May 2029; exit fee 2.5%; prepayment fees 1-7%.","Proceeds used to repay $50M prior loan to Oxford/Hercules and for general working capital.","Existing cash of $255M plus new funding extends cash runway beyond 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059109","json":"https://secwatch.observer/filing/0001104659-24-059109.json","markdown":"https://secwatch.observer/filing/0001104659-24-059109.md","text":"https://secwatch.observer/filing/0001104659-24-059109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657312/000110465924059109/0001104659-24-059109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657312/000110465924059109/tm2413907d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:12:36.434580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b9bdc578da509c293ce626c9306c449434c59fe","claim":"Verona Pharma plc entered into Credit Agreement with Oaktree Capital Management, L.P. and OCM Life Sciences Portfolio LP valued at up to $400.0 million (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024 (the “Effective Date”), Verona Pharma, Inc. (the “Borrower”), a wholly-owned subsidiary of Verona Pharma plc (the “Company”), entered into a term loan facility of up to $400.0 million (the “Term Loan”), consisting of a term loan advance in an aggregate amount of $55.0 million to be funded on the Effective Date (the “Tranche A Term Loan”), a term loan advance to be borrowed within eight business days after the occurrence of certain terms and conditions in an aggregate amount of $70.0 million (the “Tranche B Term Loan”), a term loan advance available subject to certain terms and conditions in an aggregate amount of $75.0 million (the “Tranche C Term Loan”), a term loan advance available subject to certain terms and conditions in an aggregate amount of $100.0 million (the “Tranche D Term Loan”) and a term loan advance available in the sole discretion of the lenders and subject to certain terms and conditions in an aggregate amount of up to $100.0 million (the “Tranche E Ter","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1657312/000110465924059109/0001104659-24-059109-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oaktree Capital Management, L.P. and OCM Life Sciences Portfolio LP"},{"label":"Value","value":"up to $400.0 million"},{"label":"Effective","value":"2024-05-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}